The global veterinary pain management market size is expected to reach USD 3.20 billion by 2030, registering a CAGR of 6.46% from 2024 to 2030. The primary drivers of market growth include the advent of monoclonal antibodies in OA associated pain control, rising prevalence of diseases in animals such as osteoarthritis, rising pet ownership, increasing number of veterinarians, and increasing animal health expenditure. In May 2023, Zoetis’s Librela mAb received the U.S. FDA approval for use in dog OA pain control. Moreover, pet insurance adoption is increasing due to a number of factors, including pet humanization, a growing pet population, greater initiatives by major companies, and rising veterinary care expenses.
Increasing number of veterinarians is expected to fuel the market growth. For instance, according to AVMA, there were a total of 127,131 vet practitioners in the U.S. veterinarians are now better equipped with tools and knowledge to identify and address pain in animals, whether it's acute or chronic. Moreover, there’s a greater emphasis on educating veterinarians about recognizing and managing pain in animals. Veterinary schools are incorporating pain management into their curricula, and continuing education programs keep practicing veterinarians up-to-date on the latest techniques and medications. Overall, the increasing number of veterinarians driving the veterinary pain management market reflects a positive shift towards better care and understanding of animals' needs, aligning with the broader trend of humanizing pets and recognizing their emotional and physical well-being.
Veterinary pain management has become a crucial aspect of pet care, particularly with conditions such as cancer, where pain can be a significant symptom. With the increase in cancer cases among dogs, there's likely a corresponding increase in the demand for effective pain management solutions in veterinary practice. Approximately fifty percent of dogs over the age of ten develop cancer. Cancer in dogs occurs at a rate similar to that of humans. There are certain cancers that affect cats more frequently than dogs, like lymphoma. In order to help manage pain in dogs with cancer, veterinarians frequently combine pharmaceuticals, such as analgesics and anti-inflammatory medicines, with complementary therapies, such as acupuncture and physical therapy.
Furthermore, ke, and acquisitions, regional expansions, etc., such as product launches, mergers and acquisitions, regional expansions, etc., to increase their foothold in the market. For instance, in January 2024, Ceva acquired Scout Bio, a leading biotechnology firm specializing in advanced therapies for pets. This acquisition marks a substantial advancement for Ceva, granting access to groundbreaking treatments such as monoclonal antibodies and gene therapy aimed to tackle chronic pet diseases.
This product will be delivered within 1-3 business days.
Increasing number of veterinarians is expected to fuel the market growth. For instance, according to AVMA, there were a total of 127,131 vet practitioners in the U.S. veterinarians are now better equipped with tools and knowledge to identify and address pain in animals, whether it's acute or chronic. Moreover, there’s a greater emphasis on educating veterinarians about recognizing and managing pain in animals. Veterinary schools are incorporating pain management into their curricula, and continuing education programs keep practicing veterinarians up-to-date on the latest techniques and medications. Overall, the increasing number of veterinarians driving the veterinary pain management market reflects a positive shift towards better care and understanding of animals' needs, aligning with the broader trend of humanizing pets and recognizing their emotional and physical well-being.
Veterinary pain management has become a crucial aspect of pet care, particularly with conditions such as cancer, where pain can be a significant symptom. With the increase in cancer cases among dogs, there's likely a corresponding increase in the demand for effective pain management solutions in veterinary practice. Approximately fifty percent of dogs over the age of ten develop cancer. Cancer in dogs occurs at a rate similar to that of humans. There are certain cancers that affect cats more frequently than dogs, like lymphoma. In order to help manage pain in dogs with cancer, veterinarians frequently combine pharmaceuticals, such as analgesics and anti-inflammatory medicines, with complementary therapies, such as acupuncture and physical therapy.
Furthermore, ke, and acquisitions, regional expansions, etc., such as product launches, mergers and acquisitions, regional expansions, etc., to increase their foothold in the market. For instance, in January 2024, Ceva acquired Scout Bio, a leading biotechnology firm specializing in advanced therapies for pets. This acquisition marks a substantial advancement for Ceva, granting access to groundbreaking treatments such as monoclonal antibodies and gene therapy aimed to tackle chronic pet diseases.
Veterinary Pain Management Market Report Highlights
- Based on animal type, the production animals segment accounted for the largest market share in terms of revenue in 2023, owing to the rising prevalence of chronic illnesses, greater awareness among animal health organizations, and substantial costs associated with animal healthcare in emerging economies.
- Based on product, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) segment accounted for the largest market share in terms of revenue in 2023.
- Based on indication, the osteoarthritis (OA) segment held largest market share in terms of revenue in 2023, owing to high prevalence of the disease; especially in canine animals.
- Based on end-use, hospitals & clinics segment dominated the veterinary pain management market with a share of over 82.71% in 2023.
- Based on mode of purchase, the prescription segment dominated the veterinary pain management market in 2023.
- Based on route of administration, the oral segment dominated the veterinary pain management market in 2023. Oral tablets are easier to administer compared to other forms of medication like injections.
- In 2023, North America accounted for the largest share of 38.26% in the veterinary pain management market.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Veterinary Pain Management Market Variable Trends & Scope
Chapter 4. Veterinary Pain Management Market: Animal Type Estimates & Trend Analysis
Chapter 5. Veterinary Pain Management Market: By Product Estimates & Trend Analysis
Chapter 6. Veterinary Pain Management Market: By Indication Estimates & Trend Analysis
Chapter 7. Veterinary Pain Management Market: By Route of Administration Estimates & Trend Analysis
Chapter 8. Veterinary Pain Management Market: By Mode of Purchase Estimates & Trend Analysis
Chapter 9. Veterinary Pain Management Market: By End-use Estimates & Trend Analysis
Chapter 10. Veterinary Pain Management Market: Regional Estimates & Trend Analysis
Chapter 11. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Zoetis Inc.
- VETOQUINOL.
- BOEHRINGER INGELHEIM
- Dechra Pharmaceuticals Plc (EQT)
- Merck & Co., Inc.
- CEVA ANIMAL HEALTH, LLC.
- Norbrook
- Chanelle Pharma (Exponent)
- Assisi (Wind Point Partners)
- Elanco
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 150 |
Published | June 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 2.09 Billion |
Forecasted Market Value ( USD | $ 3.2 Billion |
Compound Annual Growth Rate | 6.4% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |